AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)

Recruitingn/aAges 18 Years - anyAllCentre Hospitalier Universitaire de la Guadeloupe
💬

In plain words

What the trial is, and whether it could suit you

Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
IInclusion Criteria -Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD. MASLD is defined as evidence of hepatic steatosis associated with overweight/obesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria. * Patients affiliated with, or beneficiaries of, a social security scheme. * Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study). Exclusion Criteria: * Patients under 18 years of age. * Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.). * Presence of another cause of chronic liver disease, including: Viral hepatitis (B, C, or E) Primary biliary cholangitis or primary sclerosing cholangitis Autoimmune hepatitis Wilson's disease Hemochromatosis Alpha-1 antitrypsin deficiency Alcoholic liver disease, or daily alcohol consumption \>30 g/day for men or \>20 g/day for women -Pregnant women.
💊

What it tests

  • Not listed
📍

Where

3 sites
Centre Hospitalier Universitaire de la Guyane
Cayenne, French Guiana
CHU de la Guadeloupe
Pointe-à-Pitre, Guadeloupe
Centre Hospitalier Universitaire de la Réunion
Saint-Denis, Reunion
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy